A controlled trial of value-based insurance design - the MHealthy: Focus on Diabetes (FOD) trial

• Published in: Implementation science : IS Vol. 4; no. 1; p. 19
• Main Authors: Spaulding, Alicen, Fendrick, A Mark, Herman, William H, Stevenson, James G, Smith, Dean G, Chernew, Michael E, Parsons, Dawn M, Bruhnsen, Keith, Rosen, Allison B
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07-04-2009; BioMed Central; BMC
• Subjects: Care and treatment; Diabetes; Economic aspects; Influence; Medical care, Cost of; Out-of-pocket expenses; Patient compliance; Study Protocol; Value-based insurance design; United States
• ISSN: 1748-5908; 1748-5908
• DOI: 10.1186/1748-5908-4-19

Diabetes affects over 20 million Americans, resulting in substantial morbidity, mortality, and costs. While medications are the cornerstone of secondary prevention, many evidence-based therapies are underutilized, and patients often cite out-of-pocket costs as the reason. Value-based insurance design (VBID) is a 'clinically sensitive' refinement to benefit design which links patient cost-sharing to therapy value; the more clinically beneficial (and valuable) a therapy is for a patient, the lower that patient's cost-sharing should be. We describe the design and implementation of MHealthy: Focus on Diabetes (FOD), a prospective, controlled trial of targeted co-payment reductions for high value, underutilized therapies for individuals with diabetes.
The FOD trial includes 2,507 employees and dependents with diabetes insured by one large employer. Approximately 81% are enrolled in a single independent-practice association model health maintenance organization. The control group includes 8,637 patients with diabetes covered by other employers and enrolled in the same managed care organization. Both groups received written materials about the importance of adherence to secondary prevention therapies, while only the intervention group received targeted co-payment reductions for glycemic agents, antihypertensives, lipid-lowering agents, antidepressants, and diabetic eye exams. Primary outcomes include medication uptake and adherence. Secondary outcomes include health care utilization and expenditures. An interrupted time series, control group design will allow rigorous assessment of the intervention's impact, while controlling for unrelated temporal trends. Individual patient-level baseline data are presented.
To our knowledge, this is the first prospective controlled trial of co-payment reductions targeted to high-value services for high-risk patients. It will provide important information on feasibility of implementation and effectiveness of VBID in a real-world setting. This program has the potential for broad dissemination to other employers and insurers wishing to improve the value of their health care spending.